NASHVILLE, Tenn., August 6, 2026
Harrow Inc. announced it has entered into a definitive agreement to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., significantly strengthening its ophthalmology portfolio and expanding its presence in the dry eye disease (DED) market. TYRVAYA is the first and only FDA-approved nasal spray for the treatment of the signs and symptoms of dry eye disease, providing patients with a drop-free alternative that stimulates the body’s natural tear production. The acquisition complements Harrow’s flagship VEVYE® franchise, allowing physicians to choose between therapies targeting different mechanisms of dry eye disease. Under the agreement, Harrow will pay $30 million upfront in cash with up to $70 million in milestone payments, bringing the potential transaction value to $100 million. The company expects the transaction to close during the second half of 2026, subject to customary closing conditions.
Acquisition Strengthens Comprehensive Dry Eye Treatment Strategy
Harrow believes the addition of TYRVAYA significantly enhances its ability to serve ophthalmologists, optometrists, and patients by offering multiple therapeutic approaches for one of the world’s most common ocular disorders. Unlike conventional eye drops, TYRVAYA is administered as a nasal spray, eliminating ocular instillation-site discomfort while providing a rapid onset of tear production. According to the company, the product’s prescribing information includes no contraindications and no warnings or precautions, with transient sneezing being the most frequently reported adverse reaction. The therapy is particularly valuable for contact lens wearers, as it does not require lens removal before administration, making it the only prescription treatment offering a completely drop-free management option. Harrow expects to integrate TYRVAYA into its existing commercial infrastructure, leveraging established sales, reimbursement, medical affairs, and marketing capabilities while adding experienced personnel from Viatris to support future growth.
Transaction Expected to Accelerate Commercial Growth
Harrow executives highlighted that the acquisition aligns with the company’s disciplined capital allocation strategy while creating meaningful commercial synergies. VEVYE will remain the company’s cornerstone therapy for chronic dry eye disease by targeting the inflammatory component of DED, whereas TYRVAYA complements the portfolio by stimulating basal tear production within minutes of administration through a different biological pathway. Company leadership expects cross-promotion between the two brands to increase physician adoption, expand prescribing opportunities, and improve commercial productivity. In addition to TYRVAYA and VEVYE, Harrow’s expanding ocular surface portfolio also includes FLAREX®, a corticosteroid for steroid-responsive inflammatory eye conditions, and FreshKote® Preservative Free, an over-the-counter lubricant eye drop, creating one of the industry’s most comprehensive branded dry eye treatment franchises addressing multiple stages and mechanisms of disease.
Strategic Deal Reinforces Harrow’s Ophthalmology Leadership
The acquisition represents another milestone in Harrow’s long-term ophthalmic growth strategy, reinforcing its commitment to expanding access to differentiated eye care therapies. By combining TYRVAYA’s unique nasal spray technology with its established ophthalmic product portfolio, Harrow is positioned to provide physicians with greater flexibility in personalizing treatment for patients experiencing varying forms of dry eye disease. The company expects TYRVAYA to become financially accretive shortly after closing due to its existing commercial revenue base and compatibility with Harrow’s current operating infrastructure. As dry eye disease continues to affect millions of patients worldwide, Harrow believes this acquisition will strengthen its competitive position while supporting continued innovation and broader patient access to effective ocular therapies.
Source: Harrow press release



